Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis Article Swipe

PDF

Related Concepts

Ibrutinib Chronic lymphocytic leukemia Bruton's tyrosine kinase Ovarian cancer Medicine Cancer research Tyrosine kinase Oncology Internal medicine Leukemia Cancer Receptor

Julian Matthias Metzler , Daniel Fink , Patrick Imesch ·

YOU? · · 2020 · Open Access · · DOI: https://doi.org/10.3390/app11010222 · OA: W3113563398

Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase, an enzyme central in B cell development. It is indicated as a therapy for certain hematological diseases such as chronic lymphocytic leukemia (CLL), but also exerts off-target effects on several receptors and kinases. In this paper, we hypothesize that ibrutinib may suppress the tumor marker CA-125 in ovarian cancer. The hypothesis is based on an observation of CA-125 normalization in a patient with low-grade serous ovarian cancer who received ibrutinib for concurrent CLL. We propose a mechanistic model explaining this possible drug effect as a foundation for further research.